(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 December 2019 (12.12.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/234136 A1

(51) International Patent Classification:
C07K 14/705 (2006.01)

(21) International Application Number:
PCT/EP2019/064739

(22) International Filing Date:
05 June 2019 (05.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/680,932 05 June 2018 (05.06.2018) US

(71) Applicants: **KING'S COLLEGE LONDON** [GB/GB]; Strand, London WC2R 2LS (GB). **GAMMADELTA THERAPEUTICS LIMITED** [GB/GB]; London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH (GB).

(72) Inventors: **NUSSBAUMER, Oliver**; GammaDelta Therapeutics Limited, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH (GB). **POLYAKOVA, Oxana**; GammaDelta Therapeutics Limited, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH (GB). **MEHTA, Raj**; GammaDelta Therapeutics Limited, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH (GB). **HAYDAY, Adrian**; King's College London, Strand, London WC2R 2LS (GB). **VANTOUROUT, Pierre**; King's College London, Strand, London WC2R 2LS (GB). **ZLATAREVA, Iva**; King's College London, Strand, London WC2R 2LS (GB). **MELANDRI, Daisy**; King's College London, Strand, London WC2R 2LS (GB). **DART, Robin John Campbell**; King's College London, Strand, London WC2R 2LS (GB). **LAING, Adam**; King's College London, Strand, London WC2R 2LS (GB).

(74) Agent: **AITKEN, Elizabeth** et al.; Sagittarius IP, Marlow International, Parkway, Marlow Buckinghamshire SL7 1YL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2019/234136 A1

(54) Title: BTNL3/8 TARGETING CONSTRUCTS FOR DELIVERY OF PAYLOADS TO THE GASTROINTESTINAL SYSTEM

(57) Abstract: Protein constructs comprising a BTNL3/8 targeting moiety, a payload and an optional linker are described herein. Pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.